News | January 06, 2026
Dabur sees early demand recovery, rural sales lead growth in Q3 FY26
Within India, Dabur expects its Home & Personal Care business to deliver double-digit growth,
Within India, Dabur expects its Home & Personal Care business to deliver double-digit growth,
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
He noted the enduring relevance of Siddha medicine as “a comprehensive, preventive and sustainable healthcare system in the contemporary world
Biotium reports that GlycoLiner Labelling is fully covalent and compatible with standard fixation and permeabilization protocols
The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
The company views ESG reporting as a strategic tool to build trust with clients, investors, regulators, and stakeholders worldwide
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
Intas becomes the first and only company in India to offer IVF and gynecology therapies with needle-free injections
This production milestone positions Symbiosis at the forefront of meeting rising global demand for life-saving medicines
If approved, imlifidase has the potential to transform the kidney transplant landscape by enabling highly sensitized patients to also have access to a potentially life-changing kidney transplant
Subscribe To Our Newsletter & Stay Updated
